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Aims: Hemogram parameters in routine blood panels have been proposed as inﬂammation
markers. These parameters, especially the red cell distribution width (RDW) and mean
platelet volume (MPV), were evaluated as surrogate inﬂammatory markers in brain tumor
patients. We aimed to observe RDW and MPV values of tumor patients and compare to those
in healthy population.
Methods: We recorded white blood cell count, neutrophil count, lymphocyte count, hemo-
globin, hematocrit, RDW, platelet count, and MPV of the study group at the time of diagnosis
and compared to those of the control subjects.
Results: The RDW was signiﬁcantly elevated in study group compared to that of the control
subjects ( p = 0.001). The MPV was signiﬁcantly lower in study group than that of the control
group ( p = 0.01).
Conclusion: Decreased MPV and increased RDW were both associated with brain tumor.
However, prospective studies with larger sample sizes are needed to support the results and
expose MPV and RDW variations between metastatic and primary brain tumors.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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The inﬂammatory response plays a crucial role in neoplastic
diseases and closely correlates with tumor progression and
metastasis [1–3]. The severity of inﬂammation serves as an
important indicator of tumor progression and survival among
patients with cancer [2,4,5]. Additionally, inﬂammatory
molecules have been shown to be overexpressed by tumor
cells [6].* Corresponding author at: Abant Izzet Baysal University Hospital, Depa
fax: +90 3742534615.
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0028-3843/# 2016 Polish Neurological Society. Published by Elsevier SThe hemogram parameters in routine blood panels have
been proposed as markers of inﬂammation [7]. The size
variability of erythrocytes has been reported in terms of the
red cell distribution width (RDW) value in hemogram assays,
with higher RDW meaning higher variability. The RDW levels
are elevated in iron deﬁciency anemia. Elevation in RDW has
also been associated with inﬂammatory conditions [7–10].
Platelets are the smallest product of bone marrow in the
blood stream, and they have a crucial role in hemostasis
and inﬂammation. They are involved in the inﬂammatoryrtment of Neurosurgery, 14280 Bolu, Turkey. Tel.: +90 3742534656;
p. z o.o. All rights reserved.
Table 1 – Characteristics and data of patients in the brain tumor and control groups.
Brain tumor group Control group p
Gender Men (n) 27 26 0.83
Women (n) 21 22
Median (Min–Max)a
Age (years) 40.5 (13–71) 43 (32–51) 0.38
Lymphocyte count (k/mm3) 2 (0.7–3.8) 2.1 (1.5–3.7) 0.24
Neutrophil/lymphocyte ratio (%) 2.4 (1.1–7.5) 2 (0.6–3.5) 0.11
Hemoglobin (g/dL) 14.4 (10.2–16.4) 14.6 (12.3–17.5) 0.30
Hematocrit (%) 43 (30–50) 44 (36.5–53) 0.77
Mean corpuscular volume (fL) 86 (63–94) 87 (73–98) 0.09
Mean platelet volume (fL) 8.2 (6.3–10.5) 8.9 (6–10) 0.01
Mean  standard deviationb
White blood cell count (k/mm3) 7.5  2 7.1  1.6 0.30
Neutrophil count (k/mm3) 4.5  1.6 4.3  1.3 0.28
Red cell distribution width (%) 15.5  1.7 14.4  1.2 0.001
Platelet count (k/mm3) 255  84 256  49 0.95
aMann–Whitney U test.
bIndependent sample t-test.
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The surrogate marker of platelet activation and production is
the mean platelet volume (MPV). Various studies have shown a
relationship between the MPV and inﬂammatory diseases
[12–14]. Another inﬂammatory marker derived from a routine
blood count test is the neutrophil to lymphocyte ratio (NLCR).
NLCR has been reported as a predictive marker of outcomes in
patients treated for various cancers, such as, colorectal
adenocarcinoma [2], renal cancer [4], hepatocellular carcinoma
(HCC) [15], cancer of esophagogastric junction [16], and lung
cancer [17]. In a recent study, the preoperative NLCR corre-
sponded to glial brain tumor grading [18].
In the present retrospective study, these simple inﬂamma-
tory markers were evaluated in patients with brain tumors and
compared with those in the healthy population. These
laboratory parameters were also compared within brain
tumors of either metastatic or primary etiology, as the
radiological imaging of brain masses usually cannot differen-
tiate metastatic or primary tumors [19–21].
2. Material and methods
2.1. Subjects
The use of the data in this retrospective study was approved by
our hospital. Patients with brain tumor visited outpatient
clinics of our institution were enrolled to the study as study
group. Both primary and metastatic newly diagnosed brain
tumor cases that not received any treatment were included to
the study. None of the participants in study group were
receiving medications that may probably affect hemogram
parameters. Hemogram of the tumor patients have been
obtained at the time of diagnosis before administration of
corticosteroid therapy. The control group was selected from
patients who visited the hospital's out patient clinics for
routine checkups. Of the 48 brain tumor patients, 28 had
primary brain tumors, and 20 had metastatic tumors. For the
28 primary tumor patients, 20 had glioblastoma multiforme
(grade 4), 6 had anaplastic astrocytoma (grade 3), and 2 had
diffuse astrocytoma (grade 2). The control group was selectedfrom patients who visited the hospital's outpatient clinics for
routine checkups. None of the subjects in the study and
control groups had a history of chronic use of maintenance
medicines. The characteristics and laboratory data of the
study population are summarized in Tables 1 and 2. No
signiﬁcant difference was seen between the study and control
groups in terms of age ( p = 0.38) or gender ( p = 0.83).
2.2. Blood panel
The laboratory data of the brain tumor patients were recorded
before surgery from database of our institution. The white
blood cell count (WBC), neutrophil count (neu), lymphocyte
count (lym), hemoglobin (Hb), hematocrit (Htc), RDW, platelet
count (PLT), and MPV of the participants were obtained from
the hospital's medical database. Venous blood samples were
collected in sterile standard tubes containing constant
amounts of ethylene diamine tetraacetic acid as an anticoag-
ulant. The laboratory assessment was conducted within
several minutes after the blood samples were obtained. The
LH 780 automatic analyzer (Beckman Coulter, Inc., Brea, CA,
USA) was used for complete blood count analyses. Original kits
of the producer were used in these measurements.
2.3. Statistical analysis
All data recorded were assessed with SPSS software (SPSS 15.0;
SPSS Inc., Chicago, IL, USA). The independent samples t-test
was used for normally distributed variables and the Mann–
Whitney U test was used for non-homogeneously distributed
parameters. The primary brain tumor, metastatic brain tumor,
and control groups were compared with an ANOVA test. The
results of the statistics were expressed as either mean  SD or
median (min–max). Statistical signiﬁcance was set as p value
of lower than 0.05.
3. Results
This retrospective study examined 48 patients with brain
tumors (primary and metastatic) and 48 healthy control
Table 2 – Characteristics and data of primary and metastatic brain tumor patients.
Primary brain tumor group Metastatic tumor group p
Gender Men (n) 14 13 0.30
Women (n) 14 7
Mean  standard deviationa
Age (years) 42  16 38  16.2 0.38
White blood cell count (k/mm3) 7.5  2.1 7.4  2 0.77
Neutrophil count (k/mm3) 4.6  1.7 4.6  1.6 0.89
Lymphocyte count (k/mm3) 2  0.6 2.1  0.4 0.71
Neutrophil/lymphocyte ratio (%) 2.4  1.3 2.2  0.8 0.56
Hemoglobin (g/dL) 14.1  1.7 14  1.8 0.63
Hematocrit (%) 42.7  5.2 42.2  5.2 0.72
Mean corpuscular volume (fL) 83.5  7.9 85  6.1 0.47
Red cell distribution width (%) 15.4  1.5 15.5  1.9 0.82
Platelet count (k/mm3) 262  92 244  71 0.48
Mean platelet volume (fL) 8.2  1.2 8  1 0.49
aIndependent samples t-test.
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population are summarized in Tables 1 and 2. No signiﬁcant
difference was seen between the study and control groups in
terms of age ( p = 0.38) or gender ( p = 0.83). For the blood panel,
no difference was seen between the study and control groups
for the WBC, neu, lym, NLCR, Hb, Htc, mean corpuscular
volume, or PLT ( p > 0.05 for all). However, the mean RDW
value of the study group was signiﬁcantly elevated compared
to that of the control subjects ( p = 0.001). In addition, the MPV
of the study group was signiﬁcantly lower than that of the
control group ( p = 0.01).
The patients in the study group were further analyzed. Of
these patients, 28 had primary brain tumors and 20 had
metastatic lesions. General characteristics and laboratory
parameters of the patients with primary and metastatic
tumors are presented in Table 2. These parameters showed
no difference between primary and metastatic brain tumor
patients.
4. Discussion
This study showed that the RDW was higher and the MPV was
lower in patients with brain tumors than they were in healthy
subjects. Although the literature reported an increase in the
NLCR in neoplasms, the present study lacked such an
association. The possible mechanism for the reduction in
the MPV could be that the inﬂammatory burden interferes with
megakaryopoiesis in bone marrow, resulting in the production
of smaller platelets. Another explanation could be that the
involvement of the larger, active platelets in the inﬂammatory
microstructure and the remaining smaller, inactive platelets
cause a reduction in the MPV. Similarly, the elevation in the
RDW can be explained by the inﬂammatory situation causing
the bone marrow to produce red blood cells of different size.
Inﬂammatory molecules may alter the use of iron in bone
marrow, consequently, causing an increase in the RDW.
The studies comparing MPV in patients with malignancies
had differing results. Karaman et al. found a signiﬁcant
difference in the MPV of patients with pancreas adenocarci-
noma than that of patients with pancreatic neuroendocrine
tumor; however the age and mean Hb levels were also differentbetween the study groups [22]. Kılınçalp et al. reported higher
MPV levels in preoperative gastric cancer patients compared to
healthy subjects [23]. Similarly, a study from South Korea
evaluated MPV in HCC patients and reported an elevation in
the MPV for the patients in comparison to the control subjects
[24]. On the other hand, Aksoy et al. found the MPV and PLT
values of solid tumor patients with bone marrow metastasis to
be signiﬁcantly decreased compared to the MPV and PLT
values of healthy subjects [25]. The present study found
decreased MPV values in the brain tumor patients compared to
the controls; however, the PLT was not statistically different
between the groups.
There could be several explanations for decreased MPV in
brain tumor patients. IL-6 has been reported to be elevated in
various types of cancers [26,27] and it is also associated with
platelet production in bone marrow [28]. Increased levels of IL-
6 may interfere with platelet production, causing the creation
of smaller platelets and, thus, leading to a decrease in MPV [29].
Another speculation could be considered for the MPV decrease
in brain tumor patients. Tumors cause inﬂammation because
of the various cytokines produced by tumor cells [30] and
active platelets, which tend to be larger than rested platelets,
are involved in inﬂammatory processes. The use of the larger,
active platelets may cause a reduction in systemic MPV value
because of the remaining smaller platelets. Feng et al. [31]
demonstrated that platelets secrete and account for circulat-
ing CD40 ligand, chemokine (C-X-C motif) ligand 5, chemokine
(C-C motif) ligand 5, and epidermal growth factor by detecting
mRNA expression in platelets and megakaryocytes and
measuring cytokine levels in the platelet culture supernatants,
prion protein-derived sera, and murine immune thrombocy-
topenic purpura model. They suggested that the measurement
of platelet-speciﬁc cytokines would allow inferences concern-
ing physiology and pathophysiology in quantitative platelet
disorders.
Seretis et al. [32] studied RDW levels of breast cancer
patients and found that the RDW was higher in the patients
than it was in the controls. Elevated RDW has also been
associated with poor prognoses in multiple myeloma [33] and
lung cancer [34]. As the RDW increases in inﬂammatory status
[10], and cancer is an inﬂammatory condition, one can theorize
that the RDW will elevate in brain tumors. Our results agreed
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have shown that high RDW and low Hb levels are signiﬁcant,
independent predictors of poor survival in cancer patients and,
therefore, might be relevant prognostic factors in these
patients. In contrast, Riedl et al. [35] suggested that several
red blood cell parameters of the hemogram, including Hb
levels, might not contribute to improved risk stratiﬁcation of
cancer-associated venous thromboembolism.
Zadora et al. [18] found that glioblastoma patients had the
highest preoperative value of NLCR. An elevated preoperative
NLCR may also result from the peritumoral inﬁltration of
macrophages, which associates with an increase in cytokine
levels, such as levels of tumor necrosis factor-alpha (TNF-a),
interleukin 6, and interleukin 8 [37]. Both Glasgow prognostic
score GPS and NLCR are associated with tumor invasion and
the rate of combined CBD resection. Wu et al. [1] demonstrated
that GPS had a stronger association with clinic pathological
factors than NLCR did. As GPS is easy to measure before
starting treatment, they proposed it could be a useful tool for
the stratiﬁcation of gallbladder carcinoma patients. Bambury
et al. [38] suggested that in the future creation of prognostic
risk scores for glioblastoma multiforme, NLCR should be
considered an initial candidate variable given its ease of
measurement. Although an association has been seen
between inﬂammation and NLCR [15], the present study failed
to show such an association in brain tumor patients.
All hematologic parameters, including MPV and RDW, were
similar in patients with either primary or metastatic brain
tumors. This ﬁnding suggests that any malign neoplasm
causes similar amounts of inﬂammatory burden. However, our
cohort with primary or metastatic brain tumor was relatively
small. Larger sample sizes should show signiﬁcant differences
between primary and metastatic processes.
The results of the present study were difﬁcult to interpret
due to the retrospective design and small sample size. Another
limitation was the single center design of the work. A fourth
limitation could be that we have not compared postoperative
hemogram parameters to preoperative data. However, to the
best of our knowledge, this study was the ﬁrst in the literature
to study MPV and RDW in brain tumor patients.
5. Conclusion
The decreased MPV and increased RDW of brain tumor
patients show the usefulness of simple blood panels as
inﬂammation indicators in these patients. However, prospec-
tive studies with larger sample sizes are needed to support our
results and to expose MPV and RDW variations between
metastatic and primary brain tumors.
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